Published in Virusdisease on September 28, 2016
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature (2009) 26.47
Hepatitis C virus infection. N Engl J Med (2001) 18.67
Functions of natural killer cells. Nat Immunol (2008) 9.88
The role of the NKG2D immunoreceptor in immune cell activation and natural killing. Immunity (2002) 3.85
Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J Clin Invest (2009) 3.80
Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med (2007) 3.72
Treating viral hepatitis C: efficacy, side effects, and complications. Gut (2006) 3.71
Effect of NKG2D ligand expression on host immune responses. Immunol Rev (2010) 3.08
Natural killer cells ameliorate liver fibrosis by killing activated stellate cells in NKG2D-dependent and tumor necrosis factor-related apoptosis-inducing ligand-dependent manners. Gastroenterology (2006) 3.03
Regulation of ligands for the NKG2D activating receptor. Annu Rev Immunol (2013) 2.98
Natural killer cell functional dichotomy in chronic hepatitis B and chronic hepatitis C virus infections. Gastroenterology (2009) 2.66
NKG2D function protects the host from tumor initiation. J Exp Med (2005) 2.19
Liver natural killer and natural killer T cells: immunobiology and emerging roles in liver diseases. J Leukoc Biol (2009) 2.17
Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells. Nat Med (2013) 2.02
Increased natural cytotoxicity receptor expression and relevant IL-10 production in NK cells from chronically infected viremic HCV patients. Eur J Immunol (2007) 1.86
Interferon-alpha-induced TRAIL on natural killer cells is associated with control of hepatitis C virus infection. Gastroenterology (2010) 1.85
Reduced frequencies of NKp30+NKp46+, CD161+, and NKG2D+ NK cells in acute HCV infection may predict viral clearance. J Hepatol (2010) 1.76
Viral evasion of natural killer cells. Nat Immunol (2002) 1.74
Negative regulation of NK cell activities by inhibitory receptor CD94/NKG2A leads to altered NK cell-induced modulation of dendritic cell functions in chronic hepatitis C virus infection. J Immunol (2004) 1.59
Altered NKG2D function in NK cells induced by chronic exposure to NKG2D ligand-expressing tumor cells. Blood (2005) 1.50
Fas-ligand-mediated paracrine T cell regulation by the receptor NKG2D in tumor immunity. Nat Immunol (2006) 1.38
Activation of natural killer cells during acute infection with hepatitis C virus. Gastroenterology (2010) 1.37
Expression and function of NKG2D in CD4+ T cells specific for human cytomegalovirus. Eur J Immunol (2006) 1.35
Immunotherapy with chimeric NKG2D receptors leads to long-term tumor-free survival and development of host antitumor immunity in murine ovarian cancer. J Immunol (2008) 1.32
Hepatitis C virus (HCV) evades NKG2D-dependent NK cell responses through NS5A-mediated imbalance of inflammatory cytokines. PLoS Pathog (2010) 1.27
Natural killer cells and hepatitis C: action and reaction. Gut (2010) 1.15
Current and future therapies for hepatitis C virus infection. N Engl J Med (2013) 1.15
SHP-1-mediated inhibitory signals promote responsiveness and anti-tumour functions of natural killer cells. Nat Commun (2014) 1.07
Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response. Gastroenterology (2009) 1.05
Identification of the NKG2D haplotypes associated with natural cytotoxic activity of peripheral blood lymphocytes and cancer immunosurveillance. Cancer Res (2006) 1.05
NKG2D Ligands in Tumor Immunity: Two Sides of a Coin. Front Immunol (2015) 0.98
Hepatitis C virus in the new era: perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy. World J Gastroenterol (2014) 0.98
Association of NKG2A with treatment for chronic hepatitis C virus infection. Clin Exp Immunol (2010) 0.97
The HLA-E(R)/HLA-E(R) genotype affects the natural course of hepatitis C virus (HCV) infection and is associated with HLA-E-restricted recognition of an HCV-derived peptide by interferon-gamma-secreting human CD8(+) T cells. J Infect Dis (2009) 0.96
Decreased risk of colorectal cancer with the high natural killer cell activity NKG2D genotype in Japanese. Carcinogenesis (2008) 0.94
Impaired CD4⁺ T cell stimulation of NK cell anti-fibrotic activity may contribute to accelerated liver fibrosis progression in HIV/HCV patients. J Hepatol (2013) 0.94
Peginterferon-alpha-2a (40 kD) plus ribavirin: a review of its use in the management of chronic hepatitis C mono-infection. Drugs (2008) 0.94
NKG2D gene polymorphism has a significant impact on transplant outcomes after HLA-fully-matched unrelated bone marrow transplantation for standard risk hematologic malignancies. Haematologica (2009) 0.90
Immunity and hepatitis C: a review. Curr HIV/AIDS Rep (2013) 0.85
Phenotype and functions of natural killer cells in critically-ill septic patients. PLoS One (2012) 0.84
Association of NKG2D genetic polymorphism with susceptibility to chronic hepatitis B in a Han Chinese population. J Med Virol (2010) 0.83
Host genetic variants influencing the clinical course of Hepatitis B virus infection. J Med Virol (2015) 0.81
Review of consensus interferon in the treatment of chronic hepatitis C. Biologics (2008) 0.81
Opposite impact of NKG2D genotype by lifestyle exposure to risk of aerodigestive tract cancer among Japanese. Int J Cancer (2008) 0.81
Benefits of curing hepatitis C infection. J Gastrointestin Liver Dis (2014) 0.79
The association between single nucleotide polymorphism in interleukin-27 gene and recurrent pregnancy loss in Iranian women. Iran J Reprod Med (2015) 0.77
Development of a chamber system for rapid, high yield and cost-effective purification of deoxyribonucleic acid fragments from agarose gel. Adv Biomed Res (2014) 0.75